Provista is Bioscience Company of the Year
Clinical Research and Medical Information on the
LymPro Test
Who developed the LymPro Test?
The LymPro Test was developed and clinically evaluated by the University of Leipzig in Germany, a major European medical research university. This extremely promising test has gained significant support from the National Institute on Aging, a division of the National Institutes of Health. With this support, further clinical research of the test has been made possible.
How does the LymPro Test quantify Alzheimer’s disease?
The LymPro Test uses the proliferation of selective white blood cells in a person’s blood serum sample to quantify Alzheimer’s disease. In an initial study evaluation, the LymPro Test demonstrated both a high correlation with clinical Alzheimer’s diagnosis and the potential to diagnose the disease before the appearance of its clinical symptoms.
In an expanded second clinical study of the LymPro Test,
Provista Diagnostics, the laboratory services division of Provista Life Sciences, verified the original research by comparing 30 patients with cognitively intact controls with 26 patients with other chronic, progressive, non-Alzheimer’s dementias. Statistical comparisons were made between the test’s blinded diagnoses and the clinical diagnoses of all three cohorts. The findings include 91 percent co-positivity (Sensitivity) and 92 percent co-negativity (Specificity) for the LymPro Test with the clinical diagnosis respectively and an ROC Accuracy of 95 percent relative to clinical diagnosis.
Examination of cognitively intact and age-associated memory impairment cohort data shows that the LymPro Test can differentiate Alzheimer’s from either of these groups and has the potential for early detection and screening applications. Thus, with an ROC accuracy of 95 percent, the LymPro Test demonstrates excellent testing capabilities that far exceed the current diagnostic procedures, which require many months and several thousand dollars.